What stops Candida at the mucosal barrier

Candida albicans lives in many healthy people without causing any symptoms. The trouble starts when the fungus breaches the mucosal barrier and reaches the bloodstream — systemic infection then carries high mortality. Asking why that does not happen in most people is asking about the mechanism that holds the fungus at the boundary.

A paper published in Nature Microbiology points to the interleukin-1 family. The authors showed that Candida albicans induces specific members of that family, and their signal triggers three things at once: the production of antimicrobial peptides, an interleukin-17-dependent response, and an influx of neutrophils. Removing the family's combined signalling led to severe oropharyngeal infection.

What follows is the more interesting part. Under normal conditions the severe infection was eventually resolved by a potent neutrophil response — the immune system had a fallback. Only under neutropenic conditions, a shortage of neutrophils, did abolishing IL-1 signalling end in dissemination of the fungus, predominantly to the liver, and in death.

This mirrors the clinical picture. Neutropenia is one of the main risk factors for invasive candidiasis in people — it occurs after chemotherapy, after bone marrow transplantation and in some haematological diseases. The study shows why the defence that works in others fails specifically in those patients: the second line is missing, so damage to the first stops being recoverable.

The caveat is standard and important. This is animal work using mice lacking particular signalling components — an experimental system that can demonstrate causation but is not a human being. The result identifies a target for future therapy and explains clinical observations — it is not a treatment.

Some context the paper itself does not supply is worth adding. Drugs blocking interleukin-17 and related pathways are used today to treat psoriasis and other inflammatory conditions, and a known side effect of that class is mucosal candidiasis. This study describes the mechanism that explains the observation: switching off the pathway switches off one component of antifungal defence.

It is also worth noticing how this piece of immunity is built. It is not a single barrier but two mechanisms acting in sequence: IL-1 signalling that starts a local response, and neutrophils behind it as a reserve. Layered immunity survives the failure of one layer and only stops working when two fail together — which is exactly what was observed here.

One more point matters for readers of this site. Candida albicans is not a fungus anyone can avoid: it colonises the mucous membranes of a large share of healthy people, and that has nothing to do with hygiene or diet. What decides whether infection follows is the state of the host — not the presence of the fungus, which is the norm.

Evidence status — 29 August 2026

The paper was published on 5 August 2026. It combines experiments in human oral epithelial cells with a mouse model of oropharyngeal candidiasis. In mice, loss of the shared co-receptor for IL-1-family signals delayed antimicrobial peptides, IL-17 responses and neutrophil recruitment; when neutropenia was also induced, the fungus disseminated mainly to the liver and caused death. This is a strong mechanistic model of early mucosal protection, not a ready therapy or clinical proof in patients. Its importance lies in showing cooperation among several immune layers — and warning that simply blocking IL-1 signalling could have consequences far beyond a fungal infection.